Attention-Deficit/Hyperactivity Disorder clinical trials at UCSF
5 in progress, 1 open to eligible people
A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder
open to eligible people ages 18-55
This study will evaluate the long-term safety and tolerability of centanafadine sustained-release tablets, administered twice daily in the treatment of adults with ADHD.
San Francisco, California and other locations
A Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD)
Sorry, not yet accepting patients
The primary objective of this trial was to determine the effective doses and treatment period of PDC-1421 Capsule in subjects with ADHD. The secondary objective was to evaluate the safety of PDC-1421 Capsule in subjects receiving PDC-1421 at various dose levels.
San Francisco, California
Development of a Mobile App for an Executive Functioning Intervention for Adolescents
Sorry, not yet accepting patients
This study develops an initial prototype of a mobile tool that will support clinician-directed behavioral/organizational skills treatment for adolescents with Attention Deficit Hyperactivity Disorder (ADHD) with input guided from key stakeholders.
San Francisco, California
dHealth Solution for Improving Parent Adherence to Behavioral Treatment for ADHD
Sorry, not yet accepting patients
This study aims to develop, refine and preliminarily test a novel and scalable digital health solution designed to address parent adherence barriers in daily life contexts and increase parent's sustained use of evidence-based parenting strategies.
San Francisco, California
Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity Disorder
Sorry, in progress, not accepting new patients
To evaluate the long-term safety of SPD489 administered as a daily morning dose (5, 10, 15, 20, and 30 mg/day) in preschool children diagnosed with Attention-deficit/Hyperactivity Disorder (ADHD). Participants will be enrolled into this study from antecedent study SPD489-211 (NCT02402166) or SPD489-347 (NCT03260205) (roll-over participants) or through direct enrollment (direct enrolled pariticpants).
San Francisco, California and other locations
Last updated: